Loading...

Sinopharm Group

SEHK:1099
Snowflake Description

Proven track record and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1099
SEHK
HK$102B
Market Cap
Add to portfolio
  1. Home
    2. ›
  2. HK
    3. ›
  3. Healthcare
Last updated 2019/01/19 12:51
Company description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. The last earnings update was 121 days ago. More info.

Find similar companies

Add to Portfolio Compare Print
1099 Share Price and Events
7 Day Returns
3.6%
SEHK:1099
2.5%
HK Healthcare
1.6%
HK Market
1 Year Returns
1.3%
SEHK:1099
-16.8%
HK Healthcare
-18.9%
HK Market
1099 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sinopharm Group (1099) 3.6% 7.7% -4.7% 1.3% 23.8% 53.5%
HK Healthcare 2.5% 3.5% -4.8% -16.8% -5.8% 6.7%
HK Market 1.6% 3.5% 3.8% -18.9% 30.5% 9.9%
1 Year Return vs Industry and Market
  • 1099 outperformed the Healthcare industry which returned -16.8% over the past year.
  • 1099 outperformed the Market in Hong Kong which returned -18.9% over the past year.
Price Volatility
1099
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Sinopharm Group's competitors could be found in our database.

Value

 Is Sinopharm Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sinopharm Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sinopharm Group.

SEHK:1099 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 20 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year HK Government Bond Rate 2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SEHK:1099
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year HK Govt Bond Rate 2%
Equity Risk Premium S&P Global 8%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.5
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.499 (1 + (1- 25%) (54.71%)) 		0.704
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)		 0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2% + (0.8 * 8%) 		8.4%

Discounted Cash Flow Calculation for SEHK:1099 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sinopharm Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

SEHK:1099 DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (CNY, Millions) 8,990.00 9,509.50 11,438.00 12,859.06 14,456.67
Source Analyst x5 Analyst x6 Analyst x1 Est @ 12.42% Est @ 12.42%
Present Value
Discounted (@ 8.4%) 		8,293.31 8,092.72 8,979.56 9,312.85 9,658.50
Present value of next 5 years cash flows CN¥44,336.94
SEHK:1099 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= CN¥14,456.67 × (1 + 2%) ÷ (8.4% – 2%) 		CN¥230,496.42
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= CN¥230,496.42 ÷ (1 + 8.4%)5 		CN¥153,994.69
SEHK:1099 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= CN¥44,336.94 + CN¥153,994.69 		CN¥198,331.63
Equity Value per Share
(CNY)		 = Total value / Shares Outstanding
= CN¥198,331.63 / 2,965.52 		CN¥66.88
SEHK:1099 Discount to Share Price
Calculation Result
Exchange Rate CNY/HKD
(Reporting currency to currency of SEHK:1099) 		1.157
Value per Share
(HKD)		 = Value per Share in CNY x Exchange Rate (CNY/HKD)
= CN¥66.88 x 1.157 		HK$77.4
Value per share (HKD) From above. HK$77.40
Current discount Discount to share price of HK$34.30
= -1 x (HK$34.30 - HK$77.40) / HK$77.40 		55.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Sinopharm Group is available for.
Intrinsic value
>50%
Share price is HK$34.3 vs Future cash flow value of HK$77.4
Current Discount Checks
For Sinopharm Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Sinopharm Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Sinopharm Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sinopharm Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sinopharm Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SEHK:1099 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in CNY CN¥1.88
SEHK:1099 Share Price ** SEHK (2019-01-18) in HKD HK$34.3
SEHK:1099 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.864 CN¥29.64
Hong Kong Healthcare Industry PE Ratio Median Figure of 19 Publicly-Listed Healthcare Companies 21.44x
Hong Kong Market PE Ratio Median Figure of 1,480 Publicly-Listed Companies 10.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sinopharm Group.

SEHK:1099 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SEHK:1099 Share Price ÷ EPS (both in CNY)

= 29.64 ÷ 1.88

 15.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinopharm Group is good value based on earnings compared to the HK Healthcare industry average.
  • Sinopharm Group is overvalued based on earnings compared to the Hong Kong market.
Price based on expected Growth
Does Sinopharm Group's expected growth come at a high price?
Raw Data
SEHK:1099 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 15.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 20 Analysts		 14.1%per year
Hong Kong Healthcare Industry PEG Ratio Median Figure of 6 Publicly-Listed Healthcare Companies 1.08x
Hong Kong Market PEG Ratio Median Figure of 460 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

SEHK:1099 PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 15.76x ÷ 14.1%

 1.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinopharm Group is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Sinopharm Group's assets?
Raw Data
SEHK:1099 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in CNY CN¥13.15
SEHK:1099 Share Price * SEHK (2019-01-18) in HKD HK$34.3
SEHK:1099 Share Price converted to CNY reporting currency Exchange rate (HKD/ CNY) 0.864 CN¥29.64
Hong Kong Healthcare Industry PB Ratio Median Figure of 34 Publicly-Listed Healthcare Companies 1.72x
Hong Kong Market PB Ratio Median Figure of 2,115 Publicly-Listed Companies 0.92x
SEHK:1099 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SEHK:1099 Share Price ÷ Book Value per Share (both in CNY)

= 29.64 ÷ 13.15

 2.25x

* Primary Listing of Sinopharm Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sinopharm Group is overvalued based on assets compared to the HK Healthcare industry average.
Show me more potentially undervalued companies in the Healthcare industry
X
Value checks
We assess Sinopharm Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
    5. Sinopharm Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Sinopharm Group expected to perform in the next 1 to 3 years based on estimates from 20 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sinopharm Group expected to grow at an attractive rate?
  • Sinopharm Group's earnings growth is expected to exceed the low risk savings rate of 2%.
Growth vs Market Checks
  • Sinopharm Group's earnings growth is expected to exceed the Hong Kong market average.
  • Sinopharm Group's revenue growth is expected to exceed the Hong Kong market average.
Annual Growth Rates Comparison
Raw Data
SEHK:1099 Future Growth Rates Data Sources
Data Point Source Value (per year)
SEHK:1099 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 20 Analysts 14.1%
SEHK:1099 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 20 Analysts 10.6%
Hong Kong Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 15.6%
Hong Kong Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 12.2%
Hong Kong Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Hong Kong Market Revenue Growth Rate Market Cap Weighted Average 10.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SEHK:1099 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 20 Analyst Estimates (S&P Global) See Below
All numbers in CNY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SEHK:1099 Future Estimates Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31
2021-12-31 435,611 1
2020-12-31 382,158 10,403 7,431 18
2019-12-31 345,808 10,301 6,573 20
2018-12-31 309,327 4,533 5,682 19
SEHK:1099 Past Financials Data
Date (Data in CNY Millions) Revenue Cash Flow Net Income *
2018-06-30 287,436 3,597 5,194
2018-03-31 282,576 2,632 5,237
2017-12-31 277,717 1,667 5,280
2017-09-30 273,537 -790 5,070
2017-06-30 269,356 -3,247 4,861
2017-03-31 264,691 4,996
2016-12-31 258,388 9,258 4,635
2016-09-30 251,401 11,117 4,515
2016-06-30 244,414 12,975 4,394
2016-03-31 234,499 3,885
2015-12-31 228,673 13,412 3,772
2015-09-30 222,513 9,472 3,548

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sinopharm Group's earnings are expected to grow by 14.1% yearly, however this is not considered high growth (20% yearly).
  • Sinopharm Group's revenue is expected to grow by 10.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SEHK:1099 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 20 Analyst Estimates (S&P Global) See Below

All data from Sinopharm Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:1099 Future Estimates Data
Date (Data in CNY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31 2.64 3.06 2.48 14.00
2019-12-31 2.33 2.63 2.18 16.00
2018-12-31 2.03 2.22 1.85 15.00
SEHK:1099 Past Financials Data
Date (Data in CNY Millions) EPS *
2018-06-30 1.88
2018-03-31 1.90
2017-12-31 1.91
2017-09-30 1.84
2017-06-30 1.76
2017-03-31 1.81
2016-12-31 1.68
2016-09-30 1.63
2016-06-30 1.59
2016-03-31 1.41
2015-12-31 1.36
2015-09-30 1.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Sinopharm Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Show me more growth companies in the Healthcare industry
X
Future performance checks
We assess Sinopharm Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Hong Kong market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Hong Kong market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sinopharm Group has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Sinopharm Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sinopharm Group's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sinopharm Group's year on year earnings growth rate has been positive over the past 5 years.
  • Sinopharm Group's 1-year earnings growth is less than its 5-year average (6.8% vs 19.3%)
  • Sinopharm Group's earnings growth has exceeded the HK Healthcare industry average in the past year (6.8% vs -5.7%).
Earnings and Revenue History
Sinopharm Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sinopharm Group Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SEHK:1099 Past Revenue, Cash Flow and Net Income Data
Date (Data in CNY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 287,435.67 5,193.68 12,828.30
2018-03-31 282,576.35 5,236.80 12,207.48
2017-12-31 277,717.02 5,279.92 11,586.67
2017-09-30 273,536.65 5,070.49 11,211.18
2017-06-30 269,356.28 4,861.06 10,835.70
2017-03-31 264,690.51 4,996.12 10,875.41
2016-12-31 258,387.69 4,635.20 10,744.22
2016-09-30 251,401.06 4,514.54 10,511.51
2016-06-30 244,414.43 4,393.88 10,278.80
2016-03-31 234,498.73 3,885.30 9,963.99
2015-12-31 228,672.93 3,772.22 9,754.72
2015-09-30 222,512.99 3,547.71 9,504.17
2015-06-30 216,353.04 3,323.21 9,253.63
2015-03-31 207,865.08 3,037.20 8,889.99
2014-12-31 200,131.26 2,874.82 8,681.04
2014-09-30 190,883.36 2,719.28 8,446.76
2014-06-30 181,635.46 2,563.74 8,212.48
2014-03-31 174,250.80 2,406.87 7,899.07
2013-12-31 166,866.15 2,250.00 7,585.66
2013-09-30 158,435.94 2,211.10 7,176.19
2013-06-30 150,005.73 2,172.20 6,766.72
2013-03-31 143,253.69 2,075.79 6,552.17
2012-12-31 136,501.66 1,979.38 6,337.62
2012-09-30 128,644.35 1,857.21 6,025.20
2012-06-30 120,787.04 1,735.05 5,712.78
2012-03-31 111,505.92 1,647.83 5,300.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Sinopharm Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Sinopharm Group used its assets more efficiently than the HK Healthcare industry average last year based on Return on Assets.
  • Sinopharm Group has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Show me more strong past performing companies in the Healthcare industry
X
Past performance checks
We assess Sinopharm Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sinopharm Group has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Sinopharm Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sinopharm Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sinopharm Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sinopharm Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sinopharm Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sinopharm Group Company Filings, last reported 6 months ago.

SEHK:1099 Past Debt and Equity Data
Date (Data in CNY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 53,444.45 48,089.99 23,354.13
2018-03-31 53,444.45 48,089.99 23,354.13
2017-12-31 51,269.65 35,688.01 30,338.69
2017-09-30 51,269.65 35,688.01 30,338.69
2017-06-30 47,866.83 43,347.71 20,071.85
2017-03-31 47,866.83 43,347.71 20,071.85
2016-12-31 44,532.44 33,497.88 26,796.67
2016-09-30 44,532.44 33,497.88 26,796.67
2016-06-30 42,885.24 34,131.20 27,852.22
2016-03-31 40,655.71 28,812.19 21,147.69
2015-12-31 40,878.68 28,963.48 21,196.45
2015-09-30 40,878.68 28,963.48 21,196.45
2015-06-30 37,934.51 31,675.89 18,174.74
2015-03-31 36,289.63 29,455.45 16,423.80
2014-12-31 36,289.63 29,455.45 16,423.80
2014-09-30 36,289.63 29,455.45 16,423.80
2014-06-30 30,027.47 26,425.99 12,428.02
2014-03-31 30,027.47 26,425.99 12,428.02
2013-12-31 28,611.35 25,141.34 14,876.03
2013-09-30 28,611.35 25,141.34 14,876.03
2013-06-30 27,082.47 21,650.25 13,497.64
2013-03-31 27,082.47 21,650.25 13,497.64
2012-12-31 22,948.66 16,139.78 10,351.09
2012-09-30 22,948.66 16,139.78 10,351.09
2012-06-30 21,528.34 14,452.29 10,285.69
2012-03-31 21,528.34 14,452.29 10,285.69
  • Sinopharm Group's level of debt (90%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (80% vs 90% today).
  • Debt is not well covered by operating cash flow (7.5%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.3x coverage).
X
Financial health checks
We assess Sinopharm Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
    7. Sinopharm Group has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Sinopharm Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.92%
Current annual income from Sinopharm Group dividends. Estimated to be 2.41% next year.
If you bought HK$2,000 of Sinopharm Group shares you are expected to receive HK$38 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Sinopharm Group's pays a lower dividend yield than the bottom 25% of dividend payers in Hong Kong (2.13%).
  • Sinopharm Group's dividend is below the markets top 25% of dividend payers in Hong Kong (5.87%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SEHK:1099 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 20 Analyst Estimates (S&P Global) See Below
Hong Kong Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 13 Stocks 2.1%
Hong Kong Market Average Dividend Yield Market Cap Weighted Average of 918 Stocks 3.7%
Hong Kong Minimum Threshold Dividend Yield 10th Percentile 1.2%
Hong Kong Bottom 25% Dividend Yield 25th Percentile 2.1%
Hong Kong Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SEHK:1099 Future Dividends Estimate Data
Date (Data in CN¥) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.81 16.00
2019-12-31 0.71 18.00
2018-12-31 0.60 15.00
SEHK:1099 Past Annualized Dividends Data
Date (Data in CN¥) Dividend per share (annual) Avg. Yield (%)
2018-05-09 0.570 1.889
2017-04-20 0.500 1.735
2017-03-24 0.500 1.566
2016-06-16 0.410 1.280
2015-06-18 0.310 1.208
2014-06-20 0.260 1.140
2013-04-19 0.250 1.498
2012-03-23 0.190 1.024
2011-03-25 0.160 0.910
2010-04-16 0.010 0.040
2010-03-24 0.010 0.032

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Sinopharm Group has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Sinopharm Group only paid a dividend in the past 9 years.
Current Payout to shareholders
What portion of Sinopharm Group's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.3x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (6x coverage).
X
Income/ dividend checks
We assess Sinopharm Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sinopharm Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
    7. Sinopharm Group has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Sinopharm Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yong Liu
COMPENSATION CN¥5,876,000
AGE 49
TENURE AS CEO 1.2 years
CEO Bio

Mr. Yong Liu serves as the Chief Legal Advisor at Sinopharm Group Co. Ltd. and served as its Joint Company Secretary since October 28, 2016 until August 24, 2018. Mr. Liu is Executive Director of Sinopharm Group Co. Ltd. since December 18, 2017. Mr. Liu serves as General Manager of Beijing Sinopharm Tianyuan Property Management Co., Ltd. He joined Sinopharm Group in January 2003. He is a Chief Pharmacist and a Practicing Pharmacist. He has been General Counsel of Sinopharm Group Co. Ltd. since January 2014. He serves as General Manager of Sinopharm Holding Beijing Co.,Ltd. He serves as Executive Director of Sinopharm Group Medicine Logistic Co., Ltd. and Shanghai Huyong Medicine Co., Ltd. He has been the General Manager and the Chairman of Sinopharm Shenyang since April 2003 and January 2009 respectively. He serves as Chairman of China National Accord Medicines Corporation Ltd., (formerly known as Shenzhen Accord Pharmaceutical Co. Ltd.) since October 2017. Mr. Liu has been the President of Sinopharm Group Co. Ltd. since November 21, 2017. He served as Vice President and Secretary to the Board at Sinopharm Group Co. Ltd. since January 9, 2009 until November 21, 2017 and October 28, 2016 until November 21, 2017 respectively. He has over 24 years of working experience, over 21 years of which is management experience in the pharmaceutical and healthcare products industry. He was employed at Shanghai Pharmaceutical Station from July 1992 to July 1999 and served as the Deputy General Manager at the Marketing Department of China National Pharmaceutical Group Shanghai Corporation (China National Pharmaceutical Group Corporation) and the Deputy General Manager of Shanghai Guoda Drug Chain Store Co., Ltd. (Shanghai Guoda Drugstore Chain Co., Ltd. and Shanghai GuoDa Chain Store) from July 1999 to April 2003. He served as the General Manager and Secretary of Party Committee of Sinopharm Holding Shenyang Co., Ltd. (Sinopharm Holding Shengyang Co., Ltd.) from January 2003 to November 2009. He served as Deputy President/Deputy General Manager of Sinopharm Group Co. Ltd. since January 9, 2009. He has also been the Chairman of Sinopharm Group Chemical Reagent Co., Ltd. and Sinopharm Holding Henan Co., Ltd. (Sinopharm Henan) since February 2009. He serves as Chairman of Sinopharm Holding Beijing Tianxingpuxin BioMed Co., Ltd., Sinopharm Holding Beijing Co., Ltd., Sinopharm Holding Beijing Kangchen Bio-medicine Co., Ltd., Sinopharm Holding Guizhou Co., Ltd., Sinopharm Holding Yunnan Co., Ltd., Sinopharm Medicine Holding Beijing Huahong Co., Ltd., Sinopharm Online Co., Ltd. and China National Medicines Co., Ltd. He serves as the Chairman of Sinopharm Holding Beijing Huahong Biological Medicine Co.Ltd., Sinopharm Holding Guoda Drugstore Co., Ltd., Sinopharm Health On-line Co., Ltd., Sinopharm Holding Xinan Co., Ltd., Sinopharm Holding Chongqing Taimin Pharmaceutical Co., Ltd., Sinopharm Holding Hunan Co., Ltd., Sinopharm Holding Chongqing Co., Ltd., Sinopharm Holding Jiling Co., Ltd., Sinopharm Holding Anhui Co., Ltd., Sinopharm Group Shanghai Likang Pharmaceutical Co., Ltd., Sinopharm Holding Shandong Co., Ltd., and Sinopharm Holding Shengyang Co., Ltd. He serves as a Director of Sinopharm Guohua Network Technology Co., Ltd., Sichuan Medicine Co., Ltd., and Sinopharm Group Shanxi Co., Ltd. He has been Non-Independent Director of China National Accord Medicines Corporation Ltd. since January 18, 2017. Mr. Liu received a Bachelor's degree in Science, majoring in Business Administration of Pharmaceutical Enterprises, from China Pharmaceutical University in July 1992 and a Master's degree in Business Administration from Fudan University in January 2000. Mr. Liu holds a Doctor Degree, Pharmacist-in-Charge and Licensed Pharmacist.

CEO Compensation
  • Insufficient data for Yong to compare compensation growth.
  • Yong's remuneration is about average for companies of similar size in Hong Kong.
Management Team Tenure

Average tenure and age of the Sinopharm Group management team in years:

7.4
Average Tenure
51
Average Age
  • The average tenure for the Sinopharm Group management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Zhiming Li

TITLE
Chairman
COMPENSATION
CN¥9M
AGE
55

Yong Liu

TITLE
President & Executive Director
COMPENSATION
CN¥6M
AGE
49
TENURE
1.2 yrs

Wanyong Lian

TITLE
Vice President
AGE
47

Robert Li

TITLE
Vice President
AGE
53
TENURE
1 yrs

Xiuchang Jiang

TITLE
CFO & Vice President
AGE
54
TENURE
8.7 yrs

Qingming Yu

TITLE
Executive Director
AGE
54

Wei Liu

TITLE
Joint Company Secretary
AGE
60
TENURE
7.4 yrs

Yijian Wu

TITLE
Company Secretary
AGE
48
TENURE
0.1 yrs

Shuangjun Xu

TITLE
Non-Executive Vice President
AGE
49
TENURE
7.8 yrs

Wanjun Ma

TITLE
Vice President
AGE
49
TENURE
8.3 yrs
Board of Directors Tenure

Average tenure and age of the Sinopharm Group board of directors in years:

4.3
Average Tenure
51
Average Age
  • The tenure for the Sinopharm Group board of directors is about average.
Board of Directors

Zhiming Li

TITLE
Chairman
COMPENSATION
CN¥9M
AGE
55
TENURE
1.8 yrs

Yong Liu

TITLE
President & Executive Director
COMPENSATION
CN¥6M
AGE
49
TENURE
1.1 yrs

Qiyu Chen

TITLE
Vice Chairman
AGE
46
TENURE
5.2 yrs

Qingming Yu

TITLE
Executive Director
AGE
54
TENURE
0.6 yrs

Fang Yao

TITLE
Chairman of Supervisory Committee
AGE
49
TENURE
8 yrs

Wee Seng Tan

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥300K
AGE
62
TENURE
4.3 yrs

Zhengdong Liu

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥300K
AGE
48
TENURE
4.3 yrs

Jindong Deng

TITLE
Non-Executive Director
AGE
53
TENURE
11.4 yrs

Qunbin Wang

TITLE
Non-Executive Director
AGE
49
TENURE
16 yrs

Hailson Yu

TITLE
Independent Non-Executive Director
COMPENSATION
CN¥300K
AGE
62
TENURE
4.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (HK$) Value (HK$)
12. Jan 19 Sell Matthews International Capital Management, LLC Company 11. Jan 19 11. Jan 19 -1,109,200 HK$33.09 HK$-36,703,871
11. Dec 18 Sell OppenheimerFunds, Inc. Company 07. Dec 18 07. Dec 18 -1,214,000 HK$34.97 HK$-42,449,453
24. Oct 18 Buy J.P. Morgan Asset Management, Inc. Company 19. Oct 18 19. Oct 18 35,434 HK$35.82 HK$1,269,118
19. Oct 18 Sell J.P. Morgan Asset Management, Inc. Company 16. Oct 18 16. Oct 18 -814,948 HK$35.71 HK$-29,100,410
02. Oct 18 Sell OppenheimerFunds, Inc. Company 27. Sep 18 27. Sep 18 -1,570,000 HK$37.73 HK$-59,228,410
26. Sep 18 Sell OppenheimerFunds, Inc. Company 21. Sep 18 21. Sep 18 -1,279,200 HK$38.06 HK$-48,682,770
21. Sep 18 Sell J.P. Morgan Asset Management, Inc. Company 18. Sep 18 18. Sep 18 -1,376,188 HK$37.36 HK$-51,416,168
18. Sep 18 Sell OppenheimerFunds, Inc. Company 11. Sep 18 11. Sep 18 -406,800 HK$37.28 HK$-15,165,546
03. Aug 18 Sell OppenheimerFunds, Inc. Company 01. Aug 18 01. Aug 18 -1,270,000 HK$33.83 HK$-42,964,860
27. Jul 18 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 24. Jul 18 24. Jul 18 -233,640 HK$32.35 HK$-7,558,161
27. Jul 18 Sell J.P. Morgan Asset Management, Inc. Company 24. Jul 18 24. Jul 18 -80,000 HK$32.35 HK$-2,587,968
26. Jul 18 Buy J.P. Morgan Asset Management, Inc. Company 23. Jul 18 23. Jul 18 153,151 HK$32.37 HK$4,957,115
23. Jul 18 Sell J.P. Morgan Asset Management, Inc. Company 18. Jul 18 18. Jul 18 -26,548 HK$33.29 HK$-883,661
24. Jul 18 Sell Hongyu Zhang Individual 06. Jun 18 06. Jun 18 -30,000 HK$35.97 HK$-1,079,100
25. Jul 18 Sell OppenheimerFunds, Inc. Company 20. Jul 18 20. Jul 18 -1,887,200 HK$33.00 HK$-62,277,595
19. Jul 18 Sell JPMorgan Chase & Co, Brokerage and Securities Investments Company 16. Jul 18 16. Jul 18 -860,203 HK$33.27 HK$-28,619,986
25. Jun 18 Sell FIL Limited Company 20. Jun 18 20. Jun 18 -2,090,400 HK$32.82 HK$-68,609,850
11. Jun 18 Buy FIL Limited Company 06. Jun 18 06. Jun 18 189,600 HK$35.83 HK$6,794,164
31. May 18 Sell FIL Limited Company 28. May 18 28. May 18 -45,600 HK$35.09 HK$-1,600,040
04. May 18 Buy FIL Limited Company 30. Apr 18 30. Apr 18 1,320,800 HK$33.43 HK$44,150,252
11. Apr 18 Buy BlackRock, Inc. Company 06. Apr 18 06. Apr 18 8,776,800 HK$43.42 HK$381,079,901
27. Mar 18 Sell FIL Limited Company 22. Mar 18 22. Mar 18 -478,800 HK$36.67 HK$-17,556,159
23. Mar 18 Buy FIL Limited Company 20. Mar 18 20. Mar 18 400,800 HK$37.09 HK$14,864,388
02. Mar 18 Sell FIL Limited Company 27. Feb 18 27. Feb 18 -658,800 HK$34.62 HK$-22,806,204
14. Feb 18 Buy JPMorgan Chase & Co, Brokerage and Securities Investments Company 09. Feb 18 09. Feb 18 641,980 HK$32.55 HK$20,895,806
X
Management checks
We assess Sinopharm Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
    5. Sinopharm Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

External News
Loading...
Simply Wall St News

Is Sinopharm Group Co. Ltd.'s (HKG:1099) ROE Of 15% Impressive?

Our data shows Sinopharm Group has a return on equity of 15% for the last year. … One way to conceptualize this, is that for each HK$1 of shareholders' equity it has, the company made HK$0.15 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St - –

Can We See Significant Institutional Ownership On The Sinopharm Group Co. Ltd. (HKG:1099) Share Register?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Sinopharm Group is a pretty big company. … Check out our latest analysis for Sinopharm Group

Simply Wall St - –

Sinopharm Group Co Ltd (HKG:1099): Time For A Financial Health Check

There are a number of reasons that attract investors towards large-cap companies such as Sinopharm Group Co Ltd (HKG:1099), with a market cap of HK$97b. … This article will examine Sinopharm Group’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … See our latest analysis for Sinopharm Group

Simply Wall St - –

Want To Invest In Sinopharm Group Co Ltd (HKG:1099)? Here's How It Performed Lately

For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … 1099's trailing twelve-month earnings (from 30 June 2018) of CN¥5.2b has … However, this one-year growth rate has been lower than its average earnings growth rate over the past 5 years of 19%, indicating the rate at which 1099 is growing has slowed down

Simply Wall St - –

Know This Before Buying Sinopharm Group Co Ltd (HKG:1099) For Its Dividend

Historically, Sinopharm Group Co Ltd (HKG:1099) has been paying a dividend to shareholders. … Let's take a look at Sinopharm Group in more detail. … View our latest analysis for Sinopharm Group

Simply Wall St - –

Does Sinopharm Group Co Ltd's (HKG:1099) October Stock Price Reflect Its Future Growth?

Growth expectations for Sinopharm Group Co Ltd (HKG:1099) are high, but many investors are starting to ask whether its last close at HK$36.3 can still be rationalized by the future potential. … View our latest analysis for Sinopharm Group? … According to the analysts covering the company, the following few years should bring about good growth prospects for Sinopharm Group

Simply Wall St - –

Do You Know Sinopharm Group Co Ltd’s (HKG:1099) Cash Situation?

If you are currently a shareholder in Sinopharm Group Co Ltd (HKG:1099), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. … Today we will examine Sinopharm Group’s ability to generate cash flows, as well as the level of capital expenditure it is expected to incur over the next couple of years, which will result in how much money goes to you. … There are two methods I will use to evaluate the quality of Sinopharm Group’s FCF: firstly, I will measure its FCF yield relative to the market index yield; secondly, I will examine whether its operating cash flow will continue to grow into the future, which will give us a sense of sustainability

Simply Wall St - –

What Do You Get For Owning Sinopharm Group Co Ltd (HKG:1099)?

Your equity share is granted in return for the capital provided to the business to operate, and in order for an investment to be successful the business has to create earnings from the funds that make up this capital. … To understand Sinopharm Group’s capital returns we will look at a useful metric called return on capital employed. … Calculating Return On Capital Employed for 1099

Simply Wall St - –

Should You Be Concerned About Sinopharm Group Co Ltd's (HKG:1099) Investors?

In this article, I'm going to take a look at Sinopharm Group Co Ltd’s (HKG:1099) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … Check out our latest analysis for Sinopharm Group

Simply Wall St - –

Sinopharm Group Co Ltd (HKG:1099) Is Trading At A 45.95% Discount

How far off is Sinopharm Group Co Ltd (HKG:1099) from its intrinsic value? … by taking the foreast future cash flows of the company and discounting them back to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St - –

Company Info

Map
Description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products in the People’s Republic of China. Its Pharmaceutical Distribution segment offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. This segment distributes medicines, medical devices, and pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. The company’s Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2017, this segment had 3,834 retail pharmacies, including 2,801 directly operated by the company and 1,033 operated by franchisees. Its Other Business segment engages in the distribution of medical devices; provision of financial leasing services; and production, sale, and distribution of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Details
Name: Sinopharm Group Co. Ltd.
1099
Exchange: SEHK
Founded: 2003
HK$101,717,193,380
2,965,515,842
Website: http://www.sinopharmgroup.com.cn
Address: Sinopharm Group Co. Ltd.
Sinopharm Plaza,
No. 1001 Zhongshan Road (West),
Shanghai,
200051,
China
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SEHK 1099 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong Ltd. HK HKD 23. Sep 2009
OTCPK SHTD.F Foreign Shares-Foreign Listed Pink Sheets LLC US USD 23. Sep 2009
DB X2S Foreign Shares-Foreign Listed Deutsche Boerse AG DE EUR 23. Sep 2009
SHSC 1099 Foreign Shares-Foreign Listed Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect HK HKD 23. Sep 2009
SZSC 1099 Foreign Shares-Foreign Listed The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect HK HKD 23. Sep 2009
OTCPK SHTD.Y ADR Pink Sheets LLC US USD 30. Aug 2012
Number of employees
Current staff
Staff numbers
64,413
Sinopharm Group employees.
Industry
Health Care Distributors
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/19 12:51
End of day share price update: 2019/01/18 00:00
Last estimates confirmation: 2019/01/18
Last earnings filing: 2018/09/20
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Related Companies

© 2019 Simply Wall Street Pty Ltd, Community Design 2845206, US Design Patent #29/544/281, European Design Registration #2845206, Standard & Poor’s Financial Services LLC. All rights reserved.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2019, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2019)